While Q3 2024 saw a non-GAAP gross margin of 18.0%, management projects this to improve substantially to 39.5% in Q4 2024.
Hosted on MSN20m
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.During Q3, Eli Lilly brought in $11.4 billion in sales, up 20% from a year prior, and non-GAAP (adjusted) EPS of $1.18, which was $0.29 less than what the average of Wall Street analysts had estimated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback